{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:34:41Z","timestamp":1781231681980,"version":"3.54.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Normocalcemic primary hyperparathyroidism is a variant of primary hyperparathyroidism with consistently normal albumin-adjusted or free-ionized calcium levels. It may be an early stage of classic primary hyperparathyroidism or could represent primary kidney or bone disorder characterized by permanent elevation of PTH level. <\/jats:p><\/jats:sec><jats:sec><jats:title>Aim of the study<\/jats:title><jats:p>The study aims to compare the FGF-23 levels in patients with PHPT, NPHPT, and normal calcium and PTH levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Our study included patients who were referred to the endocrinology clinic with a presumptive diagnosis of primary hyperparathyroidism, an isolated increased level of PTH, or reduced bone densitometry. For each patient, we performed blood analysis of FGF-23, calcium, phosphate, vitamin D [25(OH)D3], estimated glomerular filtration rate (eGFR), bone turnover markers, and urine analysis for calcium\/creatinine ratio.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our study included 105 patients. Thirty patients with hypercalcemic hyperparathyroidism (HPHPT group), thirty patients with elevated PTH and normal calcium levels (NPHPT group), and 45 patients with normal calcium and PTH levels in the control group. FGF 23 level was 59.5\u00b1 23 pg\/ml in the NPHPT group, 77 \u00b1 33 pg\/ml in the HPHPT group, and 49.7 \u00b1 21.7 pg\/ml in the control group (p=0.012). The phosphate level was lowest in the HPHPT group: 2.9 \u00b1 0.6 vs 3.5 \u00b1 0.44 in the NPHPT and 3.8 \u00b1 0.5 in the control groups (p=0.001). No differences were found in eGFR, 25(OH)D3, C-terminal telopeptide type I collagen (CTX) and procollagen type 1 N-terminal propeptide (P1NP) levels, and bone densitometry scores between the three study groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings suggest that NPHPT is an early stage of PHPT. Further studies are needed to determine the role of FGF-23 and its usefulness in NPHPT.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1152464","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T13:22:16Z","timestamp":1680182536000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Normocalcemic primary hyperparathyroidism is an early stage of primary hyperparathyroidism according to fibroblast growth factor 23 level"],"prefix":"10.3389","volume":"14","author":[{"given":"Elena","family":"Chertok Shacham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimra","family":"Maman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Lazareva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refaat","family":"Masalha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lila","family":"Mahagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gala","family":"Sela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avraham","family":"Ishay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.576110","article-title":"Disorders of calcium and phosphorus metabolism and the Proteomics\/Metabolomics-based research","volume":"8","author":"Sun","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e3281ca6ffd","article-title":"Emerging role of fibroblast growth factor 23 in a bone\u2013kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization","volume":"16","author":"Liu","year":"2007","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2016.07.035","article-title":"Fgf23 and parathyroid hormone signaling interact in kidney and bone","volume":"436","author":"Andrukhova","year":"2016","journal-title":"Mol Cell Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00360.2010","article-title":"PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop","volume":"299","author":"Lavi-Moshayoff","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.130","article-title":"Hyperphosphatemia of chronic kidney disease","volume":"74","author":"Hruska","year":"2008","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006121385","article-title":"Role of hyperphosphatemia and 1,25-dihydroxyvitamin d in vascular calcification and mortality in fibroblastic growth factor 23 null mice","volume":"18","author":"Stubbs","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-013-9736-4","article-title":"Dosage effects of a phex mutation in a murine model of X-linked hypophosphatemia","volume":"93","author":"Ichikawa","year":"2013","journal-title":"Calcif Tisssue Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/81664(8)","article-title":"ADHR consortium. autosomal dominant hypophosphatemic rickets is associated with mutations in FGF-23","volume":"26","author":"White","year":"2000","journal-title":"Nat Genet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1985","article-title":"Association of serum fibroblast growth (FGF23) and incident fractures in older men: The osteoporotic fractures in men (MrOS) study","volume":"18","author":"Lane","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2019.107476","article-title":"FGF23-klotho axis as predictive factors of fractures in type 2 diabetics with early chronic kidney disease","volume":"34","author":"Ribeiro","year":"2020","journal-title":"J Diabetes Complications."},{"key":"B12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1530\/eje.0.1510055","article-title":"Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism","volume":"151","author":"Yamashita","year":"2004","journal-title":"Eur J Endo"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa084","article-title":"Normocalcemic hyperparathyroidism: Study of its prevalence and natural history","volume":"105","author":"Schini","year":"2020","journal-title":"JCEM"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021404","article-title":"Normocalcemic primary hyperparathyroidism: Evidence for generalized target-tissue resistance to parathyroid hormone","volume":"88","author":"Maruani","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1559723-15","article-title":"Clinical expression of calcium sensing receptor polymorphism (A986S) in normocalcemic and asymptomatic hyperparathyroidism","volume":"48","author":"D\u00edaz-Soto","year":"2016","journal-title":"Horm Metab Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4065\/79.12.1508","article-title":"Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin d in surgically treated primary hyperparathyroidism","volume":"79","author":"Tebben","year":"2004","journal-title":"Mayo Clinic Proc"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S253246","article-title":"Evaluation of serum level of FGF23 and 1,25(OH)2D3 in primary hyperparathyroidism patients before and after parathyroidectomy","volume":"13","author":"Hassani","year":"2020","journal-title":"Int J Gen Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2020.0030","article-title":"FGF23 and primary hyperparathyroidism: is there a link","volume":"71","author":"Bilha","year":"2020","journal-title":"Endokrynol Pol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02053","article-title":"Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism","volume":"154","author":"Kobayashi","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1530\/EJE-11-0523","article-title":"Increased circulating levels of FGF23: An adaptive response in primary hyperparathyroidism","volume":"166","author":"Witteveen","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.3390\/jcm10143089","article-title":"Assessment of clinical utility of assaying FGF-23, klotho protein, osteocalcin, NTX, and sclerostin in patients with primary hyperparathyroidism","volume":"10","author":"Syka\u0142a","year":"2021","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0430","article-title":"Perioperative changes of FGF23 in patients undergoing surgery for primary hyperparathyroidism","volume":"11","author":"Fo\u0159tov\u00e1","year":"2022","journal-title":"Endocr Connect."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2018.09.009","article-title":"Management of normocalcemic primary hyperparathyroidism","volume":"32","author":"Cusano","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2022.37.e99","article-title":"Comparisons between normocalcemic primary hyperparathyroidism and typical primary hyperparathyroidism","volume":"37","author":"Choi","year":"2022","journal-title":"J Korean Med Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10391","article-title":"Normocalcemic hyperparathyroidism: A heterogeneous disorder often misdiagnosed","volume":"4","author":"Zavatta","year":"2020","journal-title":"JBMR Plus"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2019-0325","article-title":"Low free (But not total) 25-hydroxyvitamin d levels in subjects with normocalcemic hyperparathyroidism","volume":"26","author":"Wang","year":"2020","journal-title":"Endocr Pract"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-011-0306-4","article-title":"Evaluation of a new automated chemiluminescence immunoassay for FGF23","volume":"30","author":"Shimizu","year":"2012","journal-title":"J Bone Miner Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1152464\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T13:22:18Z","timestamp":1680182538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1152464\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":27,"alternative-id":["10.3389\/fendo.2023.1152464"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1152464","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"article-number":"1152464"}}